January 27th 2020
Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.
June 30th 2015
Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.
March 22nd 2015
Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.